Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells

Faiyaz Notta, Charles G. Mullighan, Jean C. Y. Wang, Armando Poeppl, Sergei Doulatov, Letha A. Phillips, Jing Ma, Mark D. Minden, James R. Downing and John E. Dick ()
Additional contact information
Faiyaz Notta: Campbell Family Institute for Cancer Research/Ontario Cancer Institute
Charles G. Mullighan: St Jude Children’s Research Hospital
Jean C. Y. Wang: Campbell Family Institute for Cancer Research/Ontario Cancer Institute
Armando Poeppl: Campbell Family Institute for Cancer Research/Ontario Cancer Institute
Sergei Doulatov: Campbell Family Institute for Cancer Research/Ontario Cancer Institute
Letha A. Phillips: St Jude Children’s Research Hospital
Jing Ma: Hartwell Center for Bioinformatics and Biotechnology, St Jude Children’s Research Hospital
Mark D. Minden: Princess Margaret Hospital, University of Toronto
James R. Downing: St Jude Children’s Research Hospital
John E. Dick: Campbell Family Institute for Cancer Research/Ontario Cancer Institute

Nature, 2011, vol. 469, issue 7330, 362-367

Abstract: Abstract Many tumours are composed of genetically diverse cells; however, little is known about how diversity evolves or the impact that diversity has on functional properties. Here, using xenografting and DNA copy number alteration (CNA) profiling of human BCR–ABL1 lymphoblastic leukaemia, we demonstrate that genetic diversity occurs in functionally defined leukaemia-initiating cells and that many diagnostic patient samples contain multiple genetically distinct leukaemia-initiating cell subclones. Reconstructing the subclonal genetic ancestry of several samples by CNA profiling demonstrated a branching multi-clonal evolution model of leukaemogenesis, rather than linear succession. For some patient samples, the predominant diagnostic clone repopulated xenografts, whereas in others it was outcompeted by minor subclones. Reconstitution with the predominant diagnosis clone was associated with more aggressive growth properties in xenografts, deletion of CDKN2A and CDKN2B, and a trend towards poorer patient outcome. Our findings link clonal diversity with leukaemia-initiating-cell function and underscore the importance of developing therapies that eradicate all intratumoral subclones.

Date: 2011
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/nature09733 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:469:y:2011:i:7330:d:10.1038_nature09733

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature09733

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().